Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.

TitleEfficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Publication TypeJournal Article
Year of Publication2014
JournalCirculation
Volume129
Issue2
Pagination234-43
Date Published2014
ISSN0009-7322
Abstract

Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein cholesterol (LDL-C) in phase 2 studies of 12 weeks' duration. The longer-term efficacy and safety of PCSK9 inhibition remain undefined.

URLhttp://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=24255061
DOI10.1161/CIRCULATIONAHA.113.007012
Short TitleCirculation
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading